Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight
July 10, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 10, 2024 (GLOBE NEWSWIRE) -- Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The metastatic prostate cancer market is driven...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
January 19, 2023 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
December 06, 2021 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
January 28, 2021 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...